PL1824988T3 - Ukierunkowana na miejsce modyfikacja czynnika VIII - Google Patents

Ukierunkowana na miejsce modyfikacja czynnika VIII

Info

Publication number: PL1824988T3
Authority: PL; Poland
Prior art keywords: fviii; site; directed modification; modification; directed
Prior art date: 2004-11-12

Application number

PL05849392T

Other languages

English (en)

Inventor

Clark Q Pan

John E Murphy

Baisong Mei

Jonathan S Strauss

Hendri Tjandra

Jianmin Chen

Thomas Barnett

Liang Tang

Deqian Wang

Original Assignee

Bayer Healthcare Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-11-12

Filing date

2005-11-14

Publication date

2018-01-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36337298&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1824988(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-11-14 Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc

2018-01-31 Publication of PL1824988T3 publication Critical patent/PL1824988T3/pl

Links

230000004048 modification Effects 0.000 title 1
238000012986 modification Methods 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

PL05849392T 2004-11-12 2005-11-14 Ukierunkowana na miejsce modyfikacja czynnika VIII PL1824988T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US62727704P	2004-11-12	2004-11-12
EP05849392.5A EP1824988B1 (en)	2004-11-12	2005-11-14	Site-directed modification of fviii
PCT/US2005/041205 WO2006053299A2 (en)	2004-11-12	2005-11-14	Site-directed modification of fviii

Publications (1)

Publication Number	Publication Date
PL1824988T3 true PL1824988T3 (pl)	2018-01-31

Family

ID=36337298

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PL11153297.4T PL2371856T3 (pl)	2004-11-12	2005-11-14	Ukierunkowana na miejsce modyfikacja czynnika VIII
PL11153300.6T PL2363414T3 (pl)	2004-11-12	2005-11-14	Ukierunkowana na miejsce modyfikacja FVIII
PL05849392T PL1824988T3 (pl)	2004-11-12	2005-11-14	Ukierunkowana na miejsce modyfikacja czynnika VIII

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
PL11153297.4T PL2371856T3 (pl)	2004-11-12	2005-11-14	Ukierunkowana na miejsce modyfikacja czynnika VIII
PL11153300.6T PL2363414T3 (pl)	2004-11-12	2005-11-14	Ukierunkowana na miejsce modyfikacja FVIII

Country Status (32)

Country	Link
US (4)	US7632921B2 (pl)
EP (9)	EP1824988B1 (pl)
JP (5)	JP2008524117A (pl)
KR (7)	KR20120136413A (pl)
CN (6)	CN105148287B (pl)
AU (1)	AU2005304622B2 (pl)
BR (2)	BR122016022033B8 (pl)
CA (1)	CA2586379C (pl)
CY (3)	CY1119292T1 (pl)
DK (3)	DK2363414T3 (pl)
ES (4)	ES2821832T3 (pl)
FR (1)	FR19C1031I2 (pl)
HK (3)	HK1117875A1 (pl)
HN (1)	HN2007015683A (pl)
HR (2)	HRP20180481B1 (pl)
HU (5)	HUE060016T2 (pl)
IL (3)	IL182903A (pl)
LT (5)	LT1824988T (pl)
LU (1)	LUC00118I2 (pl)
MA (1)	MA29663B1 (pl)
MX (2)	MX350293B (pl)
NL (1)	NL300989I2 (pl)
NO (3)	NO20210454A1 (pl)
NZ (1)	NZ555032A (pl)
PH (2)	PH12014500352A1 (pl)
PL (3)	PL2371856T3 (pl)
PT (4)	PT1824988T (pl)
RU (1)	RU2423380C2 (pl)
SI (4)	SI2363414T1 (pl)
UA (1)	UA95225C2 (pl)
WO (1)	WO2006053299A2 (pl)
ZA (1)	ZA200703696B (pl)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL1615945T3 (pl)	2003-04-09	2012-03-30	Ratiopharm Gmbh	Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami
US9005625B2 (en)	2003-07-25	2015-04-14	Novo Nordisk A/S	Antibody toxin conjugates
US20080305992A1 (en)	2003-11-24	2008-12-11	Neose Technologies, Inc.	Glycopegylated erythropoietin
MXPA06015234A (es) *	2004-06-30	2007-11-22	Nektar Therapeutics Al Corp	Conjugados de fraccion polimero-factor ix.
EP1771066A2 (en)	2004-07-13	2007-04-11	Neose Technologies, Inc.	Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
WO2006050247A2 (en)	2004-10-29	2006-05-11	Neose Technologies, Inc.	Remodeling and glycopegylation of fibroblast growth factor (fgf)
EP1824988B1 (en)	2004-11-12	2017-04-19	Bayer HealthCare LLC	Site-directed modification of fviii
NZ556436A (en)	2005-01-10	2010-11-26	Biogenerix Ag	Glycopegylated granulocyte colony stimulating factor
EP2386571B1 (en)	2005-04-08	2016-06-01	ratiopharm GmbH	Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
WO2006134173A2 (en)	2005-06-17	2006-12-21	Novo Nordisk Health Care Ag	Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
US20070105755A1 (en)	2005-10-26	2007-05-10	Neose Technologies, Inc.	One pot desialylation and glycopegylation of therapeutic peptides
US7855279B2 (en)	2005-09-27	2010-12-21	Amunix Operating, Inc.	Unstructured recombinant polymers and uses thereof
US20090048440A1 (en)	2005-11-03	2009-02-19	Neose Technologies, Inc.	Nucleotide Sugar Purification Using Membranes
CN104593348A (zh) *	2006-05-24	2015-05-06	诺沃—诺迪斯克保健股份有限公司	具有延长的体内半寿期的因子ix类似物
ES2516694T3 (es)	2006-07-21	2014-10-31	Ratiopharm Gmbh	Glicosilación de péptidos a través de secuencias de glicosilación con unión en O
WO2008057683A2 (en)	2006-10-03	2008-05-15	Novo Nordisk A/S	Methods for the purification of polypeptide conjugates
CA2670618C (en)	2006-12-15	2016-10-04	Baxter International Inc.	Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life
BRPI0809670A8 (pt)	2007-04-03	2018-12-18	Biogenerix Ag	métodos para aumentar a produção de célula tronco, para aumentar o número de granulócitos em um indivíduo, para prevenir, tratar e aliviar a mielossupressão que resulta de uma terapia contra o câncer, para tratar uma condição em um indivíduo, para tratar neutropenia e trombocitopenia em um mamífero, para expandir células tronco hematopoiéticas em cultura, para aumentar a hematopoiese em um indivíduo, para aumentar o número de célulars progenitoras hematopoiéticas em um indivíduo, e para fornecer enxerto estável da medula óssea, e, forma de dosagem oral.
CN101778859B (zh)	2007-06-12	2014-03-26	诺和诺德公司	改良的用于生产核苷酸糖的方法
AU2008323768A1 (en) *	2007-11-09	2009-05-14	Baxter Healthcare S.A.	Modified recombinant Factor VIII and von Willebrand Factor and methods of use
CN103497246B (zh) *	2008-02-27	2016-08-10	诺沃—诺迪斯克有限公司	缀合的因子viii分子
CN102112144A (zh) *	2008-05-16	2011-06-29	拜耳医药保健有限公司	靶向性凝固因子及其使用方法
CA2726942A1 (en) *	2008-06-04	2009-12-10	Bayer Healthcare Llc	Fviii muteins for treatment of von willebrand disease
ES2654336T3 (es)	2008-06-24	2018-02-13	Csl Behring Gmbh	Factor VIII, factor de von Willebrand o sus complejos con semivida in vivo prolongada
WO2010019263A2 (en) *	2008-08-15	2010-02-18	Genzyme Corporation	Soluble flt constructs for treating cancers
SI2349342T1 (sl) *	2008-10-17	2018-10-30	Baxalta GmbH	Modificirani krvni faktorji, ki obsegajo nizko stopnjo v vodi topnega polimera
EP2352515A4 (en) *	2008-11-03	2012-04-25	Bayer Healthcare Llc	METHOD FOR TREATING HEMOPHILIA
EP2368124A4 (en) *	2008-11-24	2012-09-19	Bayer Healthcare Llc	METHOD FOR DETERMINING THE ACTIVITY OF A PEGYLATED BLOOD GENERATION FACTOR IN A SILICON-BASED ACTIVATED PART THROMBOPLASTINE TIME ASSAY
EP2387413A4 (en) *	2009-01-19	2015-12-23	Bayer Healthcare Llc	PROTEIN CONJUGATE WITH AN ENDOPEPTIDASE-SPLICABLE BIOPROTEKTIVES PART
CN102348715B (zh)	2009-02-03	2017-12-08	阿穆尼克斯运营公司	延伸重组多肽和包含该延伸重组多肽的组合物
US8716448B2 (en)	2009-02-03	2014-05-06	Amunix Operating Inc.	Coagulation factor VII compositions and methods of making and using same
EP2398822B1 (en) *	2009-02-19	2013-01-02	Novo Nordisk A/S	Modification of factor viii
KR101164453B1 (ko) *	2009-03-20	2012-07-11	한미사이언스 주식회사	위치특이적 생리활성 폴리펩타이드 결합체의 제조방법
US20120142593A1 (en) *	2009-03-24	2012-06-07	Bayer Healthcare Llc	Factor VIII Variants and Methods of Use
US8809501B2 (en)	2009-07-27	2014-08-19	Baxter International Inc.	Nucleophilic catalysts for oxime linkage
ES2597954T3 (es)	2009-07-27	2017-01-24	Baxalta GmbH	Conjugados de proteína de la coagulación sanguínea
KR101912335B1 (ko)	2009-07-27	2018-10-26	리폭센 테크놀로지즈 리미티드	비혈액 응고 단백질의 글리코폴리시알화
US8642737B2 (en)	2010-07-26	2014-02-04	Baxter International Inc.	Nucleophilic catalysts for oxime linkage
NZ623810A (en)	2009-07-27	2015-10-30	Lipoxen Technologies Ltd	Glycopolysialylation of non-blood coagulation proteins
WO2011069164A2 (en)	2009-12-06	2011-06-09	Biogen Idec Ma Inc.	Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
WO2011075185A1 (en)	2009-12-18	2011-06-23	Oligasis	Targeted drug phosphorylcholine polymer conjugates
JP5914363B2 (ja)	2010-02-16	2016-05-11	ノヴォノルディスクアー／エス	低減されたｖｗｆ結合を有する因子ｖｉｉｉ分子
EA201290804A1 (ru) *	2010-02-21	2013-03-29	БАЙЕР ХелсКер ЛЛСи	Способ активации и сопряжения биомолекул
CN106432557A (zh)	2010-04-15	2017-02-22	科迪亚科学企业公司	高分子量的含两性离子的聚合物
GB201007356D0 (en)	2010-04-30	2010-06-16	Leverton Licence Holdings Ltd	Conjugated factor VIIa
GB201007357D0 (en) *	2010-04-30	2010-06-16	Leverton Licence Holdings Ltd	Conjugated factor VIII
EP3508573A1 (en) *	2010-07-09	2019-07-10	Bioverativ Therapeutics Inc.	Systems for factor viii processing and methods thereof
SG190136A1 (en)	2010-11-05	2013-07-31	Baxter Int	A new variant of antihemophilic factor viii having increased specific activity
JP2014501227A (ja) *	2010-12-16	2014-01-20	ノヴォノルディスクアー／エス	第ｖｉｉｉ因子水溶液
BR112013015898A2 (pt)	2010-12-22	2018-06-26	Baxter International Inc.	derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada.
EP3412314A1 (en) *	2011-05-27	2018-12-12	Baxalta GmbH	Therapeutic proteins conjugated to polysialic acid and methods of preparing same
WO2012170969A2 (en)	2011-06-10	2012-12-13	Biogen Idec Ma Inc.	Pro-coagulant compounds and methods of use thereof
MX2014000031A (es)	2011-07-01	2014-07-09	Bayer Ip Gmbh	Polipeptidos de fusion de relaxina y usos de los mismos.
MY180714A (en)	2011-07-08	2020-12-07	Bioverativ Therapeutics Inc	Factor viii chimeric and hybrid polypeptides, and methods of use thereof
TWI596110B (zh)	2011-09-23	2017-08-21	諾佛儂迪克股份有限公司	新穎升糖素類似物
KR20130049671A (ko) *	2011-11-04	2013-05-14	한미사이언스 주식회사	생리활성 폴리펩타이드 결합체 제조 방법
US9458223B2 (en)	2012-02-15	2016-10-04	Csl Behring Gmbh	Von willebrand factor variants having improved factor VIII binding affinity
KR20190094480A (ko) *	2012-02-15	2019-08-13	바이오버라티브 테라퓨틱스 인크.	재조합 인자 viii 단백질
CN111548418A (zh)	2012-02-15	2020-08-18	比奥贝拉蒂治疗公司	因子viii组合物及其制备和使用方法
EP2666782A1 (en) *	2012-05-22	2013-11-27	Imnate Sarl	Coagulation factor VIII with reduced immunogenicity.
EP2858659B1 (en)	2012-06-08	2019-12-25	Bioverativ Therapeutics Inc.	Procoagulant compounds
EP3404105A1 (en)	2012-07-06	2018-11-21	Bioverativ Therapeutics Inc.	Cell line expressing single chain factor viii polypeptides and uses thereof
AU2013331000B2 (en)	2012-10-18	2018-04-19	Bioverativ Therapeutics Inc.	Methods of using a fixed dose of a clotting factor
WO2014070953A1 (en)	2012-10-30	2014-05-08	Biogen Idec Ma Inc.	Methods of Using FVIII Polypeptide
HUE047933T2 (hu)	2013-03-15	2020-05-28	Bioverativ Therapeutics Inc	Faktor VIII polipeptid készítmények
CA2905739A1 (en) *	2013-03-15	2014-09-25	Bayer Healthcare Llc	Recombinant factor viii formulations
AU2014228938B2 (en)	2013-03-15	2019-05-02	Bioverativ Therapeutics Inc.	Factor IX polypeptide formulations
WO2014170496A1 (en)	2013-04-18	2014-10-23	Novo Nordisk A/S	Stable, protracted glp-1/glucagon receptor co-agonists for medical use
EP2796145B1 (en)	2013-04-22	2017-11-01	CSL Ltd.	A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
TW201519900A (zh) *	2013-04-28	2015-06-01	Bayer Healthcare Llc	用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
EP4108254A1 (en)	2013-08-14	2022-12-28	Bioverativ Therapeutics Inc.	Recombinant factor viii proteins
TW202003554A (zh)	2013-08-14	2020-01-16	美商百歐維拉提夫治療公司	因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
JP6463361B2 (ja)	2013-09-08	2019-01-30	コディアックサイエンシーズインコーポレイテッドＫｏｄｉａｋＳｃｉｅｎｃｅｓＩｎｃ．	第ｖｉｉｉ因子両性イオンポリマーコンジュゲート
EP3060242A1 (en) *	2013-10-22	2016-08-31	DBV Technologies	Method of treating haemophilia by inducing tolerance to blood factors
WO2015070014A1 (en)	2013-11-08	2015-05-14	Biogen Idec Ma Inc.	Procoagulant fusion compound
RU2546297C1 (ru) *	2013-11-19	2015-04-10	Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук	Средство, улучшающее реологические свойства крови
EP4332839A2 (en)	2013-12-06	2024-03-06	Bioverativ Therapeutics Inc.	Population pharmacokinetics tools and uses thereof
JP6778111B2 (ja) *	2014-01-20	2020-10-28	オクタファルマ・アーゲー	ＦＶＩＩＩ：Ｃ／ＦＶＩＩＩ：Ａｇの改良された比を有する第ＶＩＩＩ因子を製造するための方法
US20160347787A1 (en)	2014-02-04	2016-12-01	Biogen Ma Inc.	Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
EP3114138B1 (en)	2014-03-05	2021-11-17	Pfizer Inc.	Improved muteins of clotting factor viii
MX2016012447A (es)	2014-03-24	2017-01-06	Biogen Ma Inc	Formulaciones de factor ix liofilizadas.
US11181534B2 (en) *	2014-04-04	2021-11-23	Bloodworks	Routine laboratory and point-of-care (POC) testing for hemostasis
US10227559B2 (en)	2014-04-10	2019-03-12	Bayer Healthcare Llc	Compounded media powder formulation and method of preparation of liquid medium for cell culture
CN106536547A (zh)	2014-06-04	2017-03-22	诺和诺德股份有限公司	用于医疗用途的glp‑1/胰高血糖素受体共激动剂
KR20170026580A (ko)	2014-07-02	2017-03-08	씨에스엘 리미티드	변형된 폰 빌레브란트 인자
MA40864A (fr)	2014-10-31	2017-09-05	Biogen Ma Inc	Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
SG11201706659WA (en)	2015-03-06	2017-09-28	Csl Behring Recombinant Facility Ag	Modified von willebrand factor having improved half-life
RU2017145002A (ru)	2015-05-22	2019-06-24	Цсл Беринг Ленгнау Аг	Способы получения модифицированного фактора фон виллебранда
AU2016266627A1 (en)	2015-05-22	2018-01-18	CSL Behring Lengnau AG	Truncated von Willebrand Factor polypeptides for treating hemophilia
JP6909203B2 (ja)	2015-08-03	2021-07-28	バイオベラティブセラピューティクスインコーポレイテッド	第ｉｘ因子融合タンパク質及びそれらの製造方法及び使用方法
US9849125B1 (en)	2015-11-03	2017-12-26	Banner Lifie Sciences LLC	Anti-overingestion dosage forms
ES2881701T3 (es)	2016-01-07	2021-11-30	CSL Behring Lengnau AG	Factor de von Willebrand mutado
RU2018128582A (ru)	2016-01-07	2020-02-11	Цсл Беринг Ленгнау Аг	Мутированный укороченный фактор фон виллебранда
US20230151078A1 (en) *	2016-06-24	2023-05-18	Mogam Instiitute For Biomedical Research	Recombinant single-chain fviii and chemical conjugate thereof
KR20190085021A (ko)	2016-11-11	2019-07-17	체에스엘 베링 렝나우 아게	혈우병을 치료하기 위한 절단된 폰 빌레브란트 인자 폴리펩타이드
TW201828974A (zh)	2016-11-11	2018-08-16	瑞士商Ｃｓｌ貝林重組技能公司	用於血管外施予以治療或預防凝血疾病之截短型類血友病因子（ｖｏｎＷｉｌｌｅｂｒａｎｄｆａｃｔｏｒ）多肽類
KR20190083355A (ko)	2016-11-16	2019-07-11	바이엘 헬쓰케어 엘엘씨	적혈구 표적화된 인자 viii 및 이를 사용하는 방법
IL266972B2 (en)	2016-12-02	2024-04-01	Bioverativ Therapeutics Inc	Methods for the treatment of hemophilic arthritis with the help of chimeric blood coagulation factors
CA3044838A1 (en)	2016-12-02	2018-06-07	Bioverativ Therapeutics Inc.	Methods of inducing immune tolerance to clotting factors
TW201831521A (zh)	2017-01-31	2018-09-01	美商生物化學醫療公司	因子ｉｘ融合蛋白以及其製備方法及使用方法
US10335375B2 (en)	2017-05-30	2019-07-02	Patheon Softgels, Inc.	Anti-overingestion abuse deterrent compositions
KR20190086269A (ko) *	2018-01-12	2019-07-22	재단법인 목암생명과학연구소	체내 지속형 재조합 당단백질 및 이의 제조방법
WO2019222682A1 (en)	2018-05-18	2019-11-21	Bioverativ Therapeutics Inc.	Methods of treating hemophilia a
CN114786731A (zh)	2019-10-10	2022-07-22	科达制药股份有限公司	治疗眼部病症的方法
WO2021091881A1 (en) *	2019-11-04	2021-05-14	The Trustees Of Columbia University In The City Of New York	High concentration cell penetrating caspase inhibitor conjugates compositions and methods thereof
CA3159985A1 (en) *	2019-12-06	2021-06-10	The Children's Hospital Of Philadelphia	Compositions and methods for modulating factor viii function

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS59172425A (ja) *	1983-03-18	1984-09-29	Nippon Chemiphar Co Ltd	新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤
US7138505B1 (en)	1984-01-12	2006-11-21	Novartis Vaccines And Diagnostics, Inc.	Factor VIII:C nucleic acid molecules
US4970300A (en)	1985-02-01	1990-11-13	New York University	Modified factor VIII
US5451521A (en)	1986-05-29	1995-09-19	Genetics Institute, Inc.	Procoagulant proteins
US5422260A (en)	1986-05-29	1995-06-06	Genetics Institute, Inc. -Legal Affairs	Human factor VIII:c muteins
US6346513B1 (en)	1987-06-12	2002-02-12	Baxter Trading Gmbh	Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US5171844A (en)	1987-06-12	1992-12-15	Gist-Brocades N.W.	Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
EP0294910B1 (en)	1987-06-12	1996-09-11	Immuno Ag	Novel proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
AU2473388A (en) *	1987-11-16	1989-06-22	Scripps Clinic And Research Foundation	Treatment of factor viii inhibitors
US5166322A (en)	1989-04-21	1992-11-24	Genetics Institute	Cysteine added variants of interleukin-3 and chemical modifications thereof
SE465222C5 (sv)	1989-12-15	1998-02-10	Pharmacia & Upjohn Ab	Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5766897A (en)	1990-06-21	1998-06-16	Incyte Pharmaceuticals, Inc.	Cysteine-pegylated proteins
US6376463B1 (en)	1992-04-07	2002-04-23	Emory University	Modified factor VIII
US6037452A (en)	1992-04-10	2000-03-14	Alpha Therapeutic Corporation	Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
JP3905921B2 (ja)	1992-10-02	2007-04-18	ジェネティクスインスチチュートリミテッドライアビリティーカンパニー	凝固第▲ｖｉｉｉ▼因子を含む組成物及びその製造方法並びに安定剤としての界面活性剤の使用方法
AU6029594A (en)	1993-01-15	1994-08-15	Enzon, Inc.	Factor viii - polymeric conjugates
SE504074C2 (sv)	1993-07-05	1996-11-04	Pharmacia Ab	Proteinberedning för subkutan, intramuskulär eller intradermal administrering
AU685187B2 (en)	1993-10-29	1998-01-15	Incyte Pharmaceuticals, Inc.	Chimeric proteins including protease nexin-1 variants
IL113010A (en)	1994-03-31	1999-10-28	Pharmacia & Upjohn Ab	Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
BE1008491A3 (fr) *	1994-07-14	1996-05-07	Croix Rouge De Belgique Depart	Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci.
WO1996041813A2 (en)	1994-11-09	1996-12-27	Offord Robin E	Functionalized polymers for site-specific attachment
WO1997001197A1 (en) *	1995-06-21	1997-01-09	Motorola Inc.	Method and antenna for providing an omnidirectional pattern
AU6486196A (en)	1995-07-11	1997-02-10	Chiron Corporation	Novel factor viii:c polypeptide analogs with altered protease sites
SE9503380D0 (sv)	1995-09-29	1995-09-29	Pharmacia Ab	Protein derivatives
AT403438B (de)	1996-05-24	1998-02-25	Immuno Ag	Pharmazeutische präparation mit faktor viii prokoagulationsaktivität und vwf-bindungsaktivität
US6458563B1 (en) *	1996-06-26	2002-10-01	Emory University	Modified factor VIII
IL128229A0 (en) *	1996-08-02	1999-11-30	Ortho Mcneil Pharm Inc	Polypeptides having a single covalently bound n-terminal water-soluble polymer
CA2225189C (en)	1997-03-06	2010-05-25	Queen's University At Kingston	Canine factor viii gene, protein and methods of use
US6753165B1 (en) *	1999-01-14	2004-06-22	Bolder Biotechnology, Inc.	Methods for making proteins containing free cysteine residues
EP1881005B1 (en)	1997-07-14	2013-04-03	Bolder Biotechnology, Inc.	Derivatives of G-CSF and related proteins
CN1113656C (zh) *	1997-10-17	2003-07-09	丰收技术股份有限公司	从富含血小板的血浆中沉淀富集生长因子的纤维蛋白原浓缩物
EP0922446A1 (en)	1997-12-03	1999-06-16	Applied Research Systems Ars Holding N.V.	Solution-phase site-specific preparation of GRF-PEG conjugates
CA2329768C (en)	1998-04-27	2008-06-10	Opperbas Holding B.V.	Pharmaceutical composition comprising factor viii and neutral liposomes
US6759216B1 (en)	1998-11-06	2004-07-06	Emory University	Glycosylated, low antigenicity low immunogenicity factor VIII
EP1129186B2 (de)	1998-11-10	2016-11-30	Stichting Sanquin Bloedvoorziening	Ein faktor viii-polypeptid mit faktor viii:c-aktivität
US6358703B1 (en)	1998-12-10	2002-03-19	Bayer Corporation	Expression system for factor VIII
US6136599A (en)	1998-12-10	2000-10-24	Bayer Corporation	Human hybrid host cell for mammalian gene expression
BR122013003013B8 (pt) *	1999-01-14	2021-07-06	Bolder Biotechnology Inc	proteína isolada monopeguilada do hormônio do crescimento e método para sua obtenção
EP1183354A2 (en)	1999-05-24	2002-03-06	The American National Red Cross	Methods of reducing factor viii clearance and compositions therefor
RU2278123C2 (ru) *	2000-02-11	2006-06-20	Максиджен Холдингз Лтд.	Молекулы, подобные фактору vii или viia
HUP0301179A3 (en)	2000-09-19	2006-11-28	Univ Emory	Modified factor viii
WO2002060951A2 (en)	2001-01-12	2002-08-08	The American National Red Cross	Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii
ES2432967T3 (es) *	2001-03-22	2013-12-05	Novo Nordisk Health Care Ag	Derivados del Factor VII de coagulación
WO2002096454A1 (en)	2001-05-31	2002-12-05	D. Collen Research Foundation Vzw	Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
WO2002098454A2 (en)	2001-05-31	2002-12-12	D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven	Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
DE60234193D1 (de)	2001-06-14	2009-12-10	Scripps Research Inst	Stabilisierte faktor viii mit gentechnisch konstruierten disulfidbindungen
EP1572889B1 (en)	2001-10-05	2008-12-17	Expression Therapeutics, LLC	Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
JP2005538694A (ja)	2002-04-18	2005-12-22	メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング	修飾されたｖｉｉｉ因子
JP4412461B2 (ja)	2002-11-20	2010-02-10	日油株式会社	修飾された生体関連物質、その製造方法および中間体
US8003117B2 (en)	2002-11-20	2011-08-23	Nof Corporation	Polyalkylene glycol derivative and modified bio-related substance
KR101025143B1 (ko)	2002-12-31	2011-04-01	넥타르 테라퓨틱스	가수분해상으로 안정한 말레이미드－종결 중합체
AU2003300139B2 (en)	2002-12-31	2008-08-28	Nektar Therapeutics	Maleamic acid polymer derivatives and their bioconjugates
KR101177340B1 (ko)	2003-01-06	2012-08-30	넥타르 테라퓨틱스	티올-선택성 수용성 중합체 유도체
HUE058897T2 (hu)	2003-02-26	2022-09-28	Nektar Therapeutics	Polimer VIII-as faktor egység konjugátumok
US20050176108A1 (en) *	2003-03-13	2005-08-11	Young-Min Kim	Physiologically active polypeptide conjugate having prolonged in vivo half-life
US20040180054A1 (en) *	2003-03-13	2004-09-16	Hanmi Pharm. Co., Ltd.	Physiologically active polypeptide conjugate having prolonged in vivo half-life
DE602004028725D1 (de) *	2003-05-12	2010-09-30	Affymax Inc	Neue poly(ethylenglycol) modifizierte erythropoietinagonisten und deren verwendungen
TR201907313T4 (tr)	2003-05-23	2019-06-21	Nektar Therapeutics	İki PEG zinciri içeren PEG türevleri.
EP1502921A1 (en)	2003-07-29	2005-02-02	ZLB Behring GmbH	Recombinant mutated human factor VIII (FVIII) with improved stability
US20050123997A1 (en)	2003-10-30	2005-06-09	Lollar John S.	Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes
US7211559B2 (en)	2003-10-31	2007-05-01	University Of Maryland, Baltimore	Factor VIII compositions and methods
DE602004026474D1 (de)	2003-12-03	2010-05-20	Univ Rochester	Rekombinanter faktor viii mit erhöhter spezifischer aktivität
WO2006027111A1 (en)	2004-09-06	2006-03-16	Zlb Behring Gmbh	Modified coagulation factor viii with enhanced stability
EP1824988B1 (en)	2004-11-12	2017-04-19	Bayer HealthCare LLC	Site-directed modification of fviii
US20080227691A1 (en)	2005-04-01	2008-09-18	Novo Nordisk Health Care Ag	Blood Coagulation FVIII Analogues
BRPI0708832A2 (pt)	2006-03-31	2011-06-14	Baxter Int	construÇço proteinÁcea
US7645860B2 (en)	2006-03-31	2010-01-12	Baxter Healthcare S.A.	Factor VIII polymer conjugates

2005
- 2005-11-14 EP EP05849392.5A patent/EP1824988B1/en active Active
- 2005-11-14 KR KR1020127028644A patent/KR20120136413A/ko not_active Application Discontinuation
- 2005-11-14 EP EP17201672.7A patent/EP3323829B1/en active Active
- 2005-11-14 JP JP2007541405A patent/JP2008524117A/ja active Pending
- 2005-11-14 KR KR1020187027821A patent/KR20180110192A/ko not_active Application Discontinuation
- 2005-11-14 HU HUE11153300A patent/HUE060016T2/hu unknown
- 2005-11-14 EP EP11153297.4A patent/EP2371856B1/en active Active
- 2005-11-14 EP EP11153300.6A patent/EP2363414B1/en active Active
- 2005-11-14 EP EP17166910.4A patent/EP3243833B1/en active Active
- 2005-11-14 EP EP16186902.9A patent/EP3153181A1/en not_active Withdrawn
- 2005-11-14 HU HUE16186901A patent/HUE050542T2/hu unknown
- 2005-11-14 NO NO20210454A patent/NO20210454A1/no unknown
- 2005-11-14 PT PT58493925T patent/PT1824988T/pt unknown
- 2005-11-14 CN CN201510612184.1A patent/CN105148287B/zh active Active
- 2005-11-14 EP EP14165736.1A patent/EP2772500B1/en not_active Revoked
- 2005-11-14 PL PL11153297.4T patent/PL2371856T3/pl unknown
- 2005-11-14 EP EP17170687.2A patent/EP3243834A1/en not_active Withdrawn
- 2005-11-14 DK DK11153300.6T patent/DK2363414T3/da active
- 2005-11-14 PH PH12014500352A patent/PH12014500352A1/en unknown
- 2005-11-14 PT PT111533006T patent/PT2363414T/pt unknown
- 2005-11-14 HR HRP20180481AA patent/HRP20180481B1/hr active IP Right Grant
- 2005-11-14 CA CA2586379A patent/CA2586379C/en active Active
- 2005-11-14 CN CN2005800464698A patent/CN101124331B/zh active Active
- 2005-11-14 MX MX2014005051A patent/MX350293B/es unknown
- 2005-11-14 UA UAA200706559A patent/UA95225C2/ru unknown
- 2005-11-14 LT LTEP05849392.5T patent/LT1824988T/lt unknown
- 2005-11-14 KR KR1020147002721A patent/KR101483917B1/ko active IP Right Grant
- 2005-11-14 KR KR1020137007423A patent/KR101468345B1/ko active Protection Beyond IP Right Term
- 2005-11-14 BR BR122016022033A patent/BR122016022033B8/pt active IP Right Grant
- 2005-11-14 SI SI200532308T patent/SI2363414T1/sl unknown
- 2005-11-14 US US11/273,896 patent/US7632921B2/en active Active
- 2005-11-14 CN CN201610201090.XA patent/CN105753968A/zh active Pending
- 2005-11-14 NO NO20200044A patent/NO345800B1/no unknown
- 2005-11-14 NZ NZ555032A patent/NZ555032A/en unknown
- 2005-11-14 ES ES16186901T patent/ES2821832T3/es active Active
- 2005-11-14 LT LTEP11153297.4T patent/LT2371856T/lt unknown
- 2005-11-14 ES ES05849392.5T patent/ES2633916T3/es active Active
- 2005-11-14 KR KR1020077013131A patent/KR101243564B1/ko active Protection Beyond IP Right Term
- 2005-11-14 SI SI200532158T patent/SI1824988T1/sl unknown
- 2005-11-14 PT PT161869011T patent/PT3130601T/pt unknown
- 2005-11-14 CN CN201210455152.1A patent/CN103102406B/zh active Active
- 2005-11-14 DK DK05849392.5T patent/DK1824988T3/en active
- 2005-11-14 BR BRPI0517795A patent/BRPI0517795B8/pt active IP Right Grant
- 2005-11-14 HU HUE05849392A patent/HUE033776T2/en unknown
- 2005-11-14 LT LTEP11153300.6T patent/LT2363414T/lt unknown
- 2005-11-14 CN CN201610838893.6A patent/CN107082806A/zh active Pending
- 2005-11-14 LT LTEP16186901.1T patent/LT3130601T/lt unknown
- 2005-11-14 SI SI200532283T patent/SI3130601T1/sl unknown
- 2005-11-14 RU RU2007121517/10A patent/RU2423380C2/ru active
- 2005-11-14 DK DK11153297.4T patent/DK2371856T3/da active
- 2005-11-14 KR KR1020147018134A patent/KR101654011B1/ko active IP Right Grant
- 2005-11-14 PT PT111532974T patent/PT2371856T/pt unknown
- 2005-11-14 AU AU2005304622A patent/AU2005304622B2/en active Active
- 2005-11-14 WO PCT/US2005/041205 patent/WO2006053299A2/en active Search and Examination
- 2005-11-14 CN CN201310125428.4A patent/CN103214569B/zh active Active
- 2005-11-14 HU HUE11153297A patent/HUE059193T2/hu unknown
- 2005-11-14 PL PL11153300.6T patent/PL2363414T3/pl unknown
- 2005-11-14 KR KR1020167023706A patent/KR101904630B1/ko active IP Right Grant
- 2005-11-14 PL PL05849392T patent/PL1824988T3/pl unknown
- 2005-11-14 SI SI200532309T patent/SI2371856T1/sl unknown
- 2005-11-14 MX MX2007005466A patent/MX2007005466A/es active IP Right Grant
- 2005-11-14 ES ES11153300T patent/ES2930159T3/es active Active
- 2005-11-14 ES ES11153297T patent/ES2930143T3/es active Active
- 2005-11-14 EP EP16186901.1A patent/EP3130601B1/en active Active
2007
- 2007-05-01 IL IL182903A patent/IL182903A/en active IP Right Grant
- 2007-05-08 ZA ZA200703696A patent/ZA200703696B/xx unknown
- 2007-05-11 HN HN2007015683A patent/HN2007015683A/es unknown
- 2007-06-06 MA MA29972A patent/MA29663B1/fr unknown
- 2007-06-08 HR HRP20070268AA patent/HRP20070268B1/hr active IP Right Grant
- 2007-06-12 NO NO20072997A patent/NO344606B1/no unknown
2008
- 2008-07-15 HK HK08107795.4A patent/HK1117875A1/xx unknown
2009
- 2009-08-13 US US12/540,703 patent/US9364520B2/en active Active
2012
- 2012-10-19 JP JP2012231926A patent/JP6109523B2/ja active Active
2013
- 2013-01-24 US US13/748,983 patent/US9096656B2/en active Active
- 2013-08-13 HK HK13109463.4A patent/HK1182121A1/xx unknown
2014
- 2014-05-11 IL IL232540A patent/IL232540A/en active IP Right Grant
- 2014-09-02 IL IL23443314A patent/IL234433B/en active IP Right Grant
2015
- 2015-02-09 JP JP2015022993A patent/JP6018238B2/ja active Active
- 2015-07-20 US US14/803,677 patent/US20160051633A1/en not_active Abandoned
2016
- 2016-06-13 HK HK16106727.9A patent/HK1218718A1/zh unknown
- 2016-12-02 JP JP2016234757A patent/JP6559642B2/ja active Active
- 2016-12-02 JP JP2016234756A patent/JP6487895B2/ja active Active
2017
- 2017-07-14 CY CY20171100753T patent/CY1119292T1/el unknown
2019
- 2019-05-07 FR FR19C1031C patent/FR19C1031I2/fr active Active
- 2019-05-07 HU HUS1900026C patent/HUS1900026I1/hu unknown
- 2019-05-08 LU LU00118C patent/LUC00118I2/fr unknown
- 2019-05-09 LT LTPA2019509C patent/LTC1824988I2/lt unknown
- 2019-05-10 CY CY2019024C patent/CY2019024I1/el unknown
- 2019-05-10 NL NL300989C patent/NL300989I2/nl unknown
- 2019-07-09 PH PH12019501613A patent/PH12019501613A1/en unknown
2020
- 2020-10-05 CY CY20201100928T patent/CY1123384T1/el unknown

Also Published As

Publication number	Publication date
KR101904630B1 (ko)	2018-10-04
ZA200703696B (en)	2008-08-27
LT2363414T (lt)	2022-10-25
EP3323829B1 (en)	2020-07-15
LTPA2019509I1 (lt)	2019-08-26
SI2371856T1 (sl)	2022-09-30
NL300989I1 (nl)	2019-05-22
HUE033776T2 (en)	2018-01-29
MX350293B (es)	2017-09-04
EP3153181A1 (en)	2017-04-12
HUE059193T2 (hu)	2022-10-28
CN101124331A (zh)	2008-02-13
US9096656B2 (en)	2015-08-04
LT3130601T (lt)	2020-09-10
HK1182121A1 (en)	2013-11-22
EP3130601B1 (en)	2020-07-15
HN2007015683A (es)	2011-07-11
EP3323829A1 (en)	2018-05-23
MX2007005466A (es)	2007-10-19
ES2930143T3 (es)	2022-12-07
CA2586379C (en)	2012-04-03
KR101654011B1 (ko)	2016-09-05
EP3243833B1 (en)	2020-06-17
CN105148287A (zh)	2015-12-16
IL232540A0 (en)	2014-06-30
CN103214569B (zh)	2016-12-28
EP2371856B1 (en)	2022-05-18
MA29663B1 (fr)	2008-08-01
EP2363414B1 (en)	2022-05-18
KR20180110192A (ko)	2018-10-08
LT1824988T (lt)	2017-10-25
BRPI0517795A8 (pt)	2018-12-26
BRPI0517795B1 (pt)	2020-03-31
AU2005304622B2 (en)	2012-03-29
KR101483917B1 (ko)	2015-01-16
PL2363414T3 (pl)	2022-09-05
FR19C1031I2 (fr)	2020-06-05
DK2363414T3 (da)	2022-08-08
HRP20180481A2 (hr)	2018-06-29
KR101243564B1 (ko)	2013-03-27
CY1119292T1 (el)	2018-02-14
RU2423380C2 (ru)	2011-07-10
HK1117875A1 (en)	2009-01-23
EP2371856A2 (en)	2011-10-05
EP3243833A1 (en)	2017-11-15
CN103102406B (zh)	2015-05-27
CN105753968A (zh)	2016-07-13
HRP20180481B1 (hr)	2022-02-18
US20100081615A1 (en)	2010-04-01
ES2821832T3 (es)	2021-04-27
PH12019501613A1 (en)	2020-09-14
US20160051633A1 (en)	2016-02-25
PT1824988T (pt)	2017-07-21
JP6109523B2 (ja)	2017-04-05
NL300989I2 (nl)	2019-11-28
LUC00118I2 (pl)	2019-12-27
HRP20070268B1 (hr)	2018-04-20
IL234433B (en)	2019-11-28
US20130274445A1 (en)	2013-10-17
RU2007121517A (ru)	2008-12-20
CY2019024I2 (el)	2019-11-27
HRP20070268A2 (en)	2007-09-30
HK1218718A1 (zh)	2017-03-10
PT2363414T (pt)	2022-08-04
LTC1824988I2 (lt)	2021-02-25
EP1824988A4 (en)	2008-12-31
KR20140091618A (ko)	2014-07-21
CN103214569A (zh)	2013-07-24
JP6487895B2 (ja)	2019-03-20
FR19C1031I1 (pl)	2019-06-28
CY2019024I1 (el)	2019-11-27
LT2371856T (lt)	2022-08-25
CY1123384T1 (el)	2021-12-31
KR20130036780A (ko)	2013-04-12
EP3130601A1 (en)	2017-02-15
BRPI0517795B8 (pt)	2021-05-25
ES2633916T3 (es)	2017-09-26
WO2006053299A3 (en)	2006-08-24
NO20200044A1 (no)	2007-06-27
SI1824988T1 (sl)	2017-11-30
HUE050542T2 (hu)	2020-12-28
IL182903A0 (en)	2007-08-19
JP2017101028A (ja)	2017-06-08
PT2371856T (pt)	2022-08-12
PT3130601T (pt)	2020-10-01
EP2371856A3 (en)	2012-03-14
EP1824988A2 (en)	2007-08-29
PH12014500352B1 (en)	2015-07-20
JP2013067621A (ja)	2013-04-18
PL2371856T3 (pl)	2022-08-22
IL182903A (en)	2014-09-30
EP2363414A2 (en)	2011-09-07
NZ555032A (en)	2010-02-26
SI3130601T1 (sl)	2020-11-30
HUS1900026I1 (hu)	2022-04-28
NO345800B1 (no)	2021-08-09
KR101468345B1 (ko)	2014-12-03
JP6559642B2 (ja)	2019-08-14
UA95225C2 (ru)	2011-07-25
NO20072997L (no)	2007-06-27
KR20120136413A (ko)	2012-12-18
EP2772500B1 (en)	2019-12-25
KR20140019489A (ko)	2014-02-14
EP2363414A3 (en)	2012-03-21
DK2371856T3 (en)	2022-08-08
JP2008524117A (ja)	2008-07-10
KR20160105928A (ko)	2016-09-07
ES2930159T3 (es)	2022-12-07
CN101124331B (zh)	2013-04-24
PH12014500352A1 (en)	2015-07-20
JP2017105773A (ja)	2017-06-15
BRPI0517795A (pt)	2008-10-21
US9364520B2 (en)	2016-06-14
AU2005304622A1 (en)	2006-05-18
DK1824988T3 (en)	2017-08-07
EP2772500A1 (en)	2014-09-03
LUC00118I1 (pl)	2019-05-13
BR122016022033B1 (pt)	2021-03-02
US7632921B2 (en)	2009-12-15
BR122016022033B8 (pt)	2021-05-25
EP1824988B1 (en)	2017-04-19
NO20210454A1 (no)	2007-06-27
SI2363414T1 (sl)	2022-09-30
CN107082806A (zh)	2017-08-22
CA2586379A1 (en)	2006-05-18
JP6018238B2 (ja)	2016-11-02
KR20070110260A (ko)	2007-11-16
CN105148287B (zh)	2019-07-09
IL232540A (en)	2017-08-31
EP3243834A1 (en)	2017-11-15
CN103102406A (zh)	2013-05-15
HUE060016T2 (hu)	2023-01-28
NO344606B1 (no)	2020-02-10
JP2015134780A (ja)	2015-07-27
WO2006053299A2 (en)	2006-05-18
US20060115876A1 (en)	2006-06-01

Publication	Publication Date	Title
HUS1900026I1 (hu)	2022-04-28	FVIII helyspecifikus módosítása
EP1785131A4 (en)	2009-03-11	EXTERNAL PREPARATION OF TYPE S / O
GB0524619D0 (en)	2006-01-11	Improved osteotome
EP1773871A4 (en)	2008-07-16	COMPOUNDS ASSOCIATED WITH TISSUE DIFFERENTIATION FACTOR AND THEIR ANALOGUES
ZA200606315B (en)	2008-02-27	Novel amido-substituted hydroxy-6-phenylphenanthridines
EP1731147A4 (en)	2010-06-30	EXTERNAL PREPARATION
PL1720633T3 (pl)	2013-04-30	Płuczka wieżowa gazu
GB0428026D0 (en)	2005-01-26	Infant aid
AU300055S (en)	2004-08-17	Scrubber
GB2416051B (en)	2006-08-30	Selection of component
ZA200508325B (en)	2008-05-28	Manufacture of kerbstones
GB0421155D0 (en)	2004-10-27	Piece of mind plan
GB0415217D0 (en)	2004-08-11	Compounds and uses thereof
GB0412872D0 (en)	2004-07-14	Novel structures
PL369353A1 (pl)	2006-02-06	Zestaw elementów budowlanych
AU157294S (en)	2005-01-17	External cornice corner member
TWM275831U (en)	2005-09-21	Improved structure of cinerary urn